首页|补肾益肺方治疗慢性阻塞性肺疾病合并骨质疏松症临床观察

补肾益肺方治疗慢性阻塞性肺疾病合并骨质疏松症临床观察

扫码查看
目的:观察补肾益肺方治疗肺肾两虚型慢性阻塞性肺疾病(COPD)稳定期合并骨质疏松症的疗效。方法:以随机数字表法将128例COPD合并骨质疏松症患者分为观察组、对照组各64例,最终122例患者完成研究,观察组62例,对照组60例。除基础治疗外,对照组加用中药安慰剂治疗,观察组加用补肾益肺方治疗。治疗3个月后观察两组急性加重次数、中医证候积分、COPD患者自我评估测试(CAT)得分、骨密度、肺功能[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占预计值的百分比(FEV1%)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)]、6min行走距离(6MWD)、视觉模拟评分法(VAS)评分、骨代谢生化标志物[I型原胶原N端前肽(PINP)、血清β胶联降解产物(β-CTX)、25-羟基维生素D(25-OH-VD)]的变化情况。结果:治疗期间两组急性加重次数比较,观察组少于对照组(P<0。05)。治疗后,两组中医证候积分、CAT评分均降低,且观察组低于对照组(P<0。05);两组肺功能指标水平均升高,且观察组FEV1、FEV1%高于对照组(P<0。05);两组6MWD均较治疗前延长,且观察组长于对照组(P<0。05);观察组VAS评分较治疗前降低,且低于治疗后对照组(P<0。05);两组β-CTX水平均较治疗前降低,且观察组低于对照组(P<0。05);两组PINP、25-OH-VD水平均较治疗前升高,且观察组高于对照组(P<0。05)。治疗期间,两组均未发生严重不良反应事件。结论:补肾益肺方治疗COPD合并骨质疏松症,可明显减少患者的急性加重次数,改善临床症状、肺功能指标及骨代谢水平。
Clinical Observation of Bushen Yifei Decoction(补肾益肺方)in Treating Chronic Obstructive Pulmonary Disease Complicated with Osteoporosis
Objective:To observe the curative effect of Bushen Yifei Decoction(补肾益肺方)in treating chronic obstructive pulmonary disease(COPD)of lung-kidney deficiency syndrome in stable stage complicated with osteoporosis.Methods:A total of 128 patients with COPD complicated with osteoporosis were divided into the observation group and the control group with random number table method,with 64 patients in each group.Finally,122 patients completed the study,with 62 patients in the observation group and 60 patients in the control group.On the basis of basic treatment,the control group was treated with Chinese medicine placebo,and the observation group was treated with Bushen Yifei Decoction.After 3 months of treatment,the number of acute exacerbations,traditional Chinese medicine(TCM)syndrome scores,COPD patient self-assessment test(CAT)scores,bone mineral density,lung function[forced expiratory volume at 1 second(FEV1),percentage of forced expiratory volume at 1 second to expected value(FEV1%),percentage of forced expiratory volume at 1 second to forced vital capacity(FEV1/FVC)],6-minute walking distance(6MWD),visual analogue scale(VAS)score for osteoporotic bone pain,bone metabolism biochemical markers[N-terminal peptide of type Ⅰ collagen(PINP),serum β Gel degradation products(β-CTX)and 25-hydroxyvitamin D(25-OH-VD)]were observed in the two groups.Results:The number of acute exacerbations in the observation group was less than that in the control group(P<0.05).After treatment,TCM syndrome score and CAT score of both groups were decreased,and the observation group was lower than the control group(P<0.05).The levels of pulmonary function indexes in both groups were increased,and FEV1 and FEV1%in the observation group were higher than those in the control group(P<0.05).6MWD in both groups was longer than that before treatment,and 6MWD in the observation group was longer than that in control group(P<0.05).VAS score in the observation group was lower than that before treatment,and lower than that in the control group after treatment(P<0.05).The level of β-CTX in both groups was lower than that before treatment,and the observation group was lower than the control group(P<0.05).The levels of PINP and 25-OH-VD in both groups were higher than those before treatment,and the observation group was higher than the control group(P<0.05).During drug treatment,neither group experienced any serious adverse reactions.Conclusion:Bushen Yifei Decoction can significantly reduce the number of acute exacerbations,relieve clinical symptoms,improve lung function indicators and bone metabolism level in treating COPD complicated with osteoporosis.

chronic obstructive pulmonary diseaseosteoporosisBushen Yifei Decoctionpulmonary functionbone metabolism

张一乐、陈旋、张艺宝、史苗颜

展开 >

上海中医药大学附属曙光医院呼吸科,上海 201203

慢性阻塞性肺疾病 骨质疏松症 补肾益肺方 肺功能 骨代谢

上海市卫生健康委员会中医药科研项目上海市科技成果转化和产业化项目

2022QN09621S21903002

2024

山东中医杂志
山东中医药学会 山东中医药大学

山东中医杂志

CSTPCD
影响因子:0.431
ISSN:0257-358X
年,卷(期):2024.43(9)